Stephen Chung, M.D.

Harold C. Simmons Comprehensive Cancer Center

Internal Medicine - Hematology/Oncology
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)

New Patient Appointment Accepting Virtual Visits or 214-645-4673

Biography

Stephen Chung, M.D., is an Assistant Professor in the Department of Internal Medicine and the Children’s Research Institute at UT Southwestern Medical Center. He specializes in the care of patients with the myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Dr. Chung earned his medical degree at Washington University School of Medicine in St. Louis. He completed a residency in internal medicine at Massachusetts General Hospital followed by a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC), where he remained as a faculty member of the Leukemia Service for six years before joining the UT Southwestern faculty in 2018.

As a postdoctoral fellow in the Human Oncology and Pathogenesis Program at MSKCC, Dr. Chung’s work led to the identification of the hematopoietic stem cell as the cell of origin for hairy cell leukemia, as well as the identification of CD99 as a disease stem cell marker and therapeutic target in MDS and AML.

Dr. Chung’s laboratory research focuses on studying the molecular alterations in the hematopoietic (blood-forming) stem cells that underlie the development of AML and MDS. By studying these immature blood cells he aims to better understand what causes these diseases, as well as the mechanisms by which they sometimes become resistant to standard therapies. He is also interested in identifying novel alterations in cell surface protein expression in these diseases to identify new therapeutic targets and to develop new diagnostic tests.

Dr. Chung has received a number of honors including a Young Investigator Award from the American Society of Clinical Oncology, a Scholar Award from the American Society of Hematology, an Early Career Award in Myelodysplastic Syndrome Research from the Dresner Foundation, a K08 Clinical Scientist Research Career Development Award, a Disease Oriented Clinical Scholars Award from UT Southwestern, and a First-Time, Tenure-Track Faculty Award from the Cancer Prevention Research Institute of Texas.

Education & Training

Residency - Massachusetts General Hospital (2006-2009), Internal Medicine
Medical School - Washington University School of Medicine (2002-2006)
Fellowship - Memorial Sloan-Kettering Cancer Center (2009-2012), Medical Oncology

Books & Publications

Publications
- Convergence of oncogenic cooperation at single-cell and single-gene levels drives leukemic transformation.
  Liu Y, Gu Z, Cao H, Kaphle P, Lyu J, Zhang Y, Hu W, Chung SS, Dickerson KE, Xu J, Nature communications 2021 11 12 1 6323
- The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
  Bergstrom CP, Dahiya S, Chen W, Zhang CC, Zhu H, Yan J, Madanat Y, Patel P, Vusirkala M, Ramakrishnan P, Rizvi S, Chung S, Awan F, Anderson LD, Collins R, Kansagra A, Leukemia research 2020 Nov 100 106480
- Banking on a cooperative effort.
  Chung SS, Leukemia & lymphoma 2019 12 60 13 3102-3103
- CD97 is a critical regulator of acute myeloid leukemia stem cell function.
  Martin GH, Roy N, Chakraborty S, Desrichard A, Chung SS, Woolthuis CM, Hu W, Berezniuk I, Garrett-Bakelman FE, Hamann J, Devlin SM, Chan TA, Park CY, The Journal of experimental medicine 2019 10 216 10 2362-2377
- Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
  Taylor J, Pavlick D, Yoshimi A, Marcelus C, Chung SS, Hechtman JF, Benayed R, Cocco E, Durham BH, Bitner L, Inoue D, Chung YR, Mullaney K, Watts JM, Diamond EL, Albacker LA, Mughal TI, Ebata K, Tuch BB, Ku N, Scaltriti M, Roshal M, Arcila M, Ali S, Hyman DM, Park JH, Abdel-Wahab O The Journal of clinical investigation 2018 Aug 128 9 3819-3825
- Aging, hematopoiesis, and the myelodysplastic syndromes.
  Chung SS, Park CY Blood advances 2017 Dec 1 26 2572-2578
- CD99 is a therapeutic target on disease stem cells in myeloid malignancies.
  Chung SS, Eng WS, Hu W, Khalaj M, Garrett-Bakelman FE, Tavakkoli M, Levine RL, Carroll M, Klimek VM, Melnick AM, Park CY Science translational medicine 2017 01 9 374
- Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.
  Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Löwenberg B, Döhner H, Döhner K, Guzman ML, Hassane DC, Roboz GJ, Grimwade D, Valk PJ, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE Nature medicine 2016 07 22 7 792-9
- CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse.
  Tamari R, Chung SS, Papadopoulos EB, Jakubowski AA, Hilden P, Devlin SM, Goldberg JD, Perales MA, Ponce DM, Sauter CS, Maloy MA, Herman DY, Klimek V, Young JW, O'Reilly RJ, Giralt SA, Castro-Malaspina H Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 Dec 21 12 2106-2114
- Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
  Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS The New England journal of medicine 2015 Oct 373 18 1733-47
- miR-29a maintains mouse hematopoietic stem cell self-renewal by regulating Dnmt3a.
  Hu W, Dooley J, Chung SS, Chandramohan D, Cimmino L, Mukherjee S, Mason CE, de Strooper B, Liston A, Park CY Blood 2015 Apr 125 14 2206-16
- Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.
  Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O Science translational medicine 2014 May 6 238 238ra71
- Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
  Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R Science translational medicine 2014 Feb 6 224 224ra25
- Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia.
  Shih AH, Chung SS, Dolezal EK, Zhang SJ, Abdel-Wahab OI, Park CY, Nimer SD, Levine RL, Klimek VM Haematologica 2013 Jun 98 6 908-12
- Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.
  Dey BR, Chung SS, Spitzer TR, Zheng H, Macgillivray TE, Seldin DC, McAfee S, Ballen K, Attar E, Wang T, Shin J, Newton-Cheh C, Moore S, Sanchorawala V, Skinner M, Madsen JC, Semigran MJ Transplantation 2010 Oct 90 8 905-11

Clinical Focus

Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)